UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 477.131

Sortiert nach

Complete Teardown Report of Gionee's S Plus

M2 Presswire, 2017-05-22

2017

Volltextzugriff (PDF)

Complete Teardown Report of Gionee's S Plus - Research and Markets

Business Wire, 2017-05-22

2017

Volltextzugriff (PDF)

Siemens Recalls MicroScan Synergies plus and rapID/S plus Gram Negative Panels

Business Wire, 2013-09-16

2013

Volltextzugriff (PDF)

Insightful's S-PLUS(R) Selected as a KMWorld Trend Setting Product of 2006; S-PLUS Recognized for Delivering Predictive Analytics across the Enterprise

Business Wire, 2006-08-28, p.1

2006

Volltextzugriff (PDF)

Research and Markets: Time Series: Applications to Finance with R and S-Plus(R), 2nd Edition

M2 Presswire, 2011-01-26

2011

Volltextzugriff (PDF)

Research and Markets: Time Series: Applications to Finance with R and S-Plus(R), 2nd Edition

Business Wire, 2011-01-26

2011

Volltextzugriff (PDF)

New Michelin Sport A/S Plus Tire Provides Unrivaled Performance and an Extended Mileage Warranty

PR newswire, 2008-06-25

2008

Volltextzugriff (PDF)

New Michelin(R) Pilot(R) Sport A/S Plus Tire Provides Unrivaled Performance and an Extended Mileage Warranty

PR newswire, 2008-06-25

2008

Volltextzugriff (PDF)

MathSoft Introduces Next Generation of S-PLUS for Unix on Solaris; Major Upgrade Includes New Core Technology for Analyzing Large Data Sets; Enhanced Financial Time Series Functionality

Business Wire, 1998-08-10

1998

Volltextzugriff (PDF)

Insightful Corporation Schedules Announcement of Financial Results for Second Quarter 2006

Business Wire, 2006-07-20, p.1

2006

Volltextzugriff (PDF)

Insightful's Dr. Michael O'Connell to Participate in DIA's Webinar on Safety Data Analysis and Reporting; Experts from the FDA, Pharmaceutical Industry and Insightful to Participate

Business Wire, 2005-11-22, p.1

2005

Volltextzugriff (PDF)

Rapidly Progressing Advanced Non-Small Cell Lung Cancer Patients Shown to Benefit in New CYRAMZA (ramucirumab) Phase 3 Subgroup Analysis

PR newswire, 2017-10-16

2017

Volltextzugriff (PDF)

Gran Tierra Energy Announces 2014 Year-End Reserves

PR newswire, 2015-02-02

2015

Volltextzugriff (PDF)

Lilly Builds Upon Body of Clinical Evidence for CYRAMZA (ramucirumab) with Phase 3 RANGE Data Demonstrating Superior Progression-Free Survival in Advanced or Metastatic Urothelial Cancer

PR newswire, 2017-09-10

2017

Volltextzugriff (PDF)

Lilly's CYRAMZA (ramucirumab) Phase 3 RELAY Trial Met Primary Endpoint, Significantly Improving Progression-Free Survival in First-Line Treatment of Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

PR newswire, 2019-03-12

2019

Volltextzugriff (PDF)

Lilly's CYRAMZA (ramucirumab) Receives Fourth FDA Approval

PR newswire, 2015-04-24

2015

Volltextzugriff (PDF)

Early-Phase Immuno-Oncology Studies of Lilly's ALIMTA (pemetrexed) and CYRAMZA (ramucirumab) with Merck's KEYTRUDA (pembrolizumab) Show Encouraging Results in Non-Small Cell Lung Cancer

PR newswire, 2016-06-05

2016

Volltextzugriff (PDF)

Early-Phase Immuno-Oncology Studies of Lilly's ALIMTA Show Encouraging Results in Non-Small Cell Lung Cancer

PR newswire, 2016-06-05

2016

Volltextzugriff (PDF)

Lilly Phase 3 REACH-2 Trial Data Published in The Lancet Oncology Shows Improvement in Overall Survival with CYRAMZA (ramucirumab) in Second-Line AFP-High Hepatocellular Carcinoma Patients

PR newswire, 2019-01-18

2019

Volltextzugriff (PDF)

Lilly Reports Additional Top-Line Results from CYRAMZA (ramucirumab) Phase 3 RANGE Study in Advanced or Metastatic Urothelial Cancer

PR newswire, 2018-04-20

2018

Volltextzugriff (PDF)

Lilly Reports Top-Line Results from CYRAMZA (ramucirumab) Phase 3 Study in First-Line Advanced Gastric Cancer

PR newswire, 2017-12-08

2017

Volltextzugriff (PDF)

Greif Reports First Quarter 2022 Results

PR newswire, 2022-03-02

2022

Volltextzugriff (PDF)

Lilly Announces Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA (ramucirumab) Met Primary Endpoint, Improving Progression-Free Survival

PR newswire, 2017-05-31

2017

Volltextzugriff (PDF)

Lilly Announces CYRAMZA (ramucirumab) Phase 3 REACH-2 Study in Second-Line Hepatocellular Carcinoma Patients Met Overall Survival Endpoint

PR newswire, 2018-04-04

2018

Volltextzugriff (PDF)

CYRAMZA (ramucirumab) Hepatocellular Carcinoma Data Published by The Lancet Oncology

PR newswire, 2015-06-19

2015

Volltextzugriff (PDF)

1 – 25 von 477.131

Suche als RSS-Feed

Aktive Filter

ThemaComputer Software Industry

PublikationsformZeitungsartikel

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Mit Volltextzugriff
(3.588)

Sprache

Englisch
(477.126)
Französisch
(6)

Erscheinungsjahr

n.n

Thema

Forecasts And Trends
(13.651)
Company Sales And Earnings
(12.631)
Pharmaceutical Industry
(11.398)
Company Earnings/profit
(10.895)
Banking Industry
(8.494)
Market Trend/market Analysis
(7.550)
Airlines
(6.409)
Communications Industry
(6.118)
Telecommunications Services Industry
(6.115)
Securities
(5.669)
Finance
(5.145)
Real Estate Investment Trusts
(4.996)
Semiconductor Industry
(4.519)
Care And Treatment
(4.518)
Officials And Employees
(4.464)
Insurance Industry
(4.384)
Contracts
(4.236)
Mergers, Acquisitions And Divestments
(4.176)
Cable Television Broadcasting Industry
(4.071)
Information Services
(4.030)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Nexis Uni
(471.117)
EBSCOhost Business Source Ultimate
(402)
EZB Electronic Journals Library
(19)
Literature Online (LION)
(9)
Worldwide Political Science Abstracts
(6)
Sociological Abstracts
(3)
Applied Social Sciences Index & Abstracts (ASSIA)
(2)

2 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Pr Newswire
(206.396)
Business Wire
(115.702)
M2 Presswire
(69.689)
Daily Herald
(43.195)
Bbc Monitoring International Reports
(9.704)
Wisconsin State Journal
(4.236)
Philippine Daily Inquirer
(3.766)
The Columbian
(3.685)
Business Line
(2.679)
Allafrica.Com
(2.040)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Complete Teardown Report of Gionee's S Plus

Complete Teardown Report of Gionee's S Plus - Research and Markets

Siemens Recalls MicroScan Synergies plus and rapID/S plus Gram Negative Panels

Insightful's S-PLUS(R) Selected as a KMWorld Trend Setting Product of 2006; S-PLUS Recognized for Delivering Predictive Analytics across the Enterprise

Research and Markets: Time Series: Applications to Finance with R and S-Plus(R), 2nd Edition

Research and Markets: Time Series: Applications to Finance with R and S-Plus(R), 2nd Edition

New Michelin Sport A/S Plus Tire Provides Unrivaled Performance and an Extended Mileage Warranty

New Michelin(R) Pilot(R) Sport A/S Plus Tire Provides Unrivaled Performance and an Extended Mileage Warranty

MathSoft Introduces Next Generation of S-PLUS for Unix on Solaris; Major Upgrade Includes New Core Technology for Analyzing Large Data Sets; Enhanced Financial Time Series Functionality

Insightful Corporation Schedules Announcement of Financial Results for Second Quarter 2006

Insightful's Dr. Michael O'Connell to Participate in DIA's Webinar on Safety Data Analysis and Reporting; Experts from the FDA, Pharmaceutical Industry and Insightful to Participate

Rapidly Progressing Advanced Non-Small Cell Lung Cancer Patients Shown to Benefit in New CYRAMZA (ramucirumab) Phase 3 Subgroup Analysis

Gran Tierra Energy Announces 2014 Year-End Reserves

Lilly Builds Upon Body of Clinical Evidence for CYRAMZA (ramucirumab) with Phase 3 RANGE Data Demonstrating Superior Progression-Free Survival in Advanced or Metastatic Urothelial Cancer

Lilly's CYRAMZA (ramucirumab) Phase 3 RELAY Trial Met Primary Endpoint, Significantly Improving Progression-Free Survival in First-Line Treatment of Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

Lilly's CYRAMZA (ramucirumab) Receives Fourth FDA Approval

Early-Phase Immuno-Oncology Studies of Lilly's ALIMTA (pemetrexed) and CYRAMZA (ramucirumab) with Merck's KEYTRUDA (pembrolizumab) Show Encouraging Results in Non-Small Cell Lung Cancer

Early-Phase Immuno-Oncology Studies of Lilly's ALIMTA Show Encouraging Results in Non-Small Cell Lung Cancer

Lilly Phase 3 REACH-2 Trial Data Published in The Lancet Oncology Shows Improvement in Overall Survival with CYRAMZA (ramucirumab) in Second-Line AFP-High Hepatocellular Carcinoma Patients

Lilly Reports Additional Top-Line Results from CYRAMZA (ramucirumab) Phase 3 RANGE Study in Advanced or Metastatic Urothelial Cancer

Lilly Reports Top-Line Results from CYRAMZA (ramucirumab) Phase 3 Study in First-Line Advanced Gastric Cancer

Greif Reports First Quarter 2022 Results

Lilly Announces Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA (ramucirumab) Met Primary Endpoint, Improving Progression-Free Survival

Lilly Announces CYRAMZA (ramucirumab) Phase 3 REACH-2 Study in Second-Line Hepatocellular Carcinoma Patients Met Overall Survival Endpoint

CYRAMZA (ramucirumab) Hepatocellular Carcinoma Data Published by The Lancet Oncology

Aktive Filter

Suchergebnisse filtern